The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Lamotrigine in the Immediate Treatment of Outpatients With Depersonalization Disorder Without Psychiatric Comorbidity: Randomized, Double-Blind, Placebo-Controlled Study
Abstract
OBJECTIVE: Depersonalization disorders (DPDs) are highly prevalent in population. However, the effect of lamotrigine on outpatients with DPD without psychiatric comorbidity has not been studied in a double-blind placebo-controlled design. METHOD: Eighty patients (all men) were washed out from all medications. Each patient was randomized either to receive lamotrigine (40 patients) for 12 weeks or matched on placebo (40 patients) in a double-blind manner. Eligible participants, in addition to meeting the criteria for DPD from Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision, were required to be between 18 and 65 years. Response was defined as a 50% reduction in the Cambridge Depersonalization Scale. Response effects with lamotrigine and placebo were compared by using analysis of variance and χ² tests. Six patients did not return for at least 1 subsequent assessment, and 74 patients dropped out (36 taking lamotrigine and 38 taking placebo) in the valuables study group. RESULTS: Of the 36 lamotrigine-treated participants, 26 responded by 12 weeks versus 6 of the 38 placebo-treated participants (P < 0.001). The most common and problematic adverse effect in the lamotrigine group was rash. CONCLUSIONS: The authors believe this to be the first double-blind placebo-controlled randomization study to test the efficacy of lamotrigine in the management of outpatients with DPDs. These need to be replicated in a larger study group.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, a trial of lamotrigine for dissociative symptoms which reported positive results was recently retracted [137].”
From Treatment of dissociative identity disorder: leveraging neurobiology to optimize success (2024) · cites this paper as [137]
Citations
Cites
The Cambridge Depersonalisation Scale: a new instrument for the measurement of depersonalisation
Sierra, M., & Berrios, G. E. (2000) · Psychiatry Research · doi:10.1016/s0165-1781(00)00100-1 · Cited by 467
Anand, A., Charney, D. S., Oren, D. A., Berman, R. M., Hu, X. S., Cappiello, A., & Krystal, J. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.270 · Cited by 426 · cited 2×
“In the absence of large-scale randomized controlled trials and in the presence of conflicting published data (see below), the efficacy of lamotrigine (whether as monotherapy or in conjunction with an SSRI) is not yet firmly established, but it is often the first-line treatment for the condition.(7) In an initial study…”
BackgroundEnadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans
Walsh, S., Strain, E., Abreu, M., & Bigelow, G. (2001) · Psychopharmacology · doi:10.1007/s002130100788 · Cited by 258 · cited 1×
“However, 1 open-label study has found evidence of a role for the opioid receptor antagonist naltrexone in treating dissociative symptoms in the context of borderline personality disorder,(19) and it may be of note that the selective kappa opioid receptor agonist enadoline has been found to induce depersonalization, al…”
BackgroundDepersonalisation Disorder: A Contemporary Overview
Simeon, D. (2004) · CNS Drugs · doi:10.2165/00023210-200418060-00002 · Cited by 198
Bohus, M. J., Landwehrmeyer, G. B., Stiglmayr, C. E., Limberger, M. F., Böhme, R., & Schmahl, C. G. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0906 · Cited by 153
Cellular and Molecular Actions of Lamotrigine: Possible Mechanisms of Efficacy in Bipolar Disorder
Xie, X., & Hagan, R. M. (1998) · Neuropsychobiology · doi:10.1159/000026527 · Cited by 128 · cited 5×
“Nevertheless, these findings provide evidence that lamotrigine treatment is well tolerated and may be proposed as an effective therapeutic strategy to improve outcome in treatment of DPD.”
BackgroundInfluentialThe phenomenological stability of depersonalization: comparing the old with the new
SIERRA, M., & BERRIOS, G. E. (2001) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-200109000-00010 · Cited by 100 · cited 1×
“In an initial study of monotherapy of lamotrigine in 4 patients with primary depersonalization found substantial benefits in all cases.(21) A subsequent placebo-controlled crossover study of 9 patients found no significant benefits from the drug.”
BackgroundUnderstanding and treating depersonalisation disorder
Medford, N., Sierra, M., Baker, D., & David, A. S. (2005) · Advances in Psychiatric Treatment · doi:10.1192/apt.11.2.92 · Cited by 100
A placebo-controlled, cross-over trial of lamotrigine in depersonalization disorder
Sierra, M., Phillips, M. L., Ivin, G., Krystal, J., & David, A. S. (2003) · Journal of Psychopharmacology · doi:10.1177/0269881103017001712 · Cited by 73 · cited 4×
“A small controlled trial found no efficacy for lamotrigine.(9) During the past decade, anecdotal reports of improvement in depersonalization with selective serotonin reuptake inhibitors or clomipramine(13) have been made.”
BackgroundInfluentialThe potential role of lamotrigine in schizophrenia
Large, C. H., Webster, E. L., & Goff, D. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0020-9 · Cited by 69
Research works printed but not linked: 2
- Fichtner, 1992, Am J Psychiatry, 149, 1750
- Ratliff, 1995, Am J Psychiatry, 152, 1689
Cited by
A pharmacological overview of lamotrigine for the treatment of epilepsy
Ramesh, Y. V., Jakki, S. L., Venkatachalam, S., Eswaramoorthy, M., Shanmuganathan, S., Karuppaiah, A., & Nanjan, M. J. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1254041 · Cited by 55
“LTG is superior to placebo for the treatment of posttraumatic stress disorder [103] and depersonalization disorders [104].”
BackgroundLamotrigine in epilepsy, pregnancy and psychiatry – a drug for all seasons?
Vajda, F. J. E., Dodd, S., & Horgan, D. (2012) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2012.05.024 · Cited by 48
Pharmacotherapy for dissociative disorders: A systematic review
Sutar, R., & Sahu, S. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112529 · Cited by 42
Lamotrigine Uses in Psychiatric Practice
Naguy, A., & Al-Enezi, N. (2017) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000535 · Cited by 34
Evidence-based treatment for Depersonalisation-derealisation Disorder (DPRD)
Somer, E., Williams, T., & Stein, D. J. (2013) · BMC Psychology · doi:10.1186/2050-7283-1-20 · Cited by 30
Metadata
- Authors
- Aliyev, N. A., & Aliyev, Z. N.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2011-02
- Volume
- 31
- Issue
- 1
- Pages
- 61-65
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2037805349
- Cited by
- 28
- References
- 22
- Citations by year
- 2026: 1 · 2024: 1 · 2020: 1 · 2019: 3 · 2017: 4 · 2016: 3 · 2015: 1 · 2014: 5 · 2013: 4 · 2012: 4
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Status
- Retracted
- Update notices
- retraction (2014-12-01)
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Psychosomatic Disorders and Their Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- lamotrigine, depersonalization disorder, outpatients, psychiatric comorbidity, antiepileptic drugs, adverse effects, rash
- MeSH terms
- Lamotrigine, Adult, Ambulatory Care, Depersonalization, Double-Blind Method, Humans, Male, Middle Aged, Time Factors, Triazines, Comorbidity, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lamotrigine in the Immediate Treatment of Outpatients With Depersonalization Disorder Without Psychiatric Comorbidity: Randomized, Double-Blind, Placebo-Controlled Study. https://app.cochat.ai/papers/10.1097/jcp.0b013e31820428e1
- The paper
- Aliyev, N. A., & Aliyev, Z. N. (2011). Lamotrigine in the Immediate Treatment of Outpatients With Depersonalization Disorder Without Psychiatric Comorbidity: Randomized, Double-Blind, Placebo-Controlled Study. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e31820428e1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.